URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Jane Henderson Biography and Net Worth

CFO of Apogee Therapeutics

Jane Henderson has served as Chief Financial Officer since January 2023. Prior to joining Apogee, Ms. Henderson served as the Chief Financial Officer and Chief Business Officer of Adagio Therapeutics, Inc. (now Invivyd, Inc.). She has also served as Chief Financial Officer of Turnstone Biologics Corp., Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc., and as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in health care investment banking. During the past five years, Ms. Henderson has served on the board of directors of Cargo Therapeutics, Inc., Akero Therapeutics, Inc., IVERIC Bio, Inc., and Ventus Therapeutics, Inc. Ms. Henderson also serves on the Dedman College Executive Board of Southern Methodist University. Ms. Henderson received a B.S. in psychology from Duke University. She is passionate about music and animal rescue (resulting in a menagerie of dogs and horses in her family).

What is Jane Henderson's net worth?: The estimated net worth of Jane Henderson is at least $9.58 million as of August 23rd, 2024. Ms. Henderson owns 200,871 shares of Apogee Therapeutics stock worth more than $9,583,555 as of December 21st. This net worth evaluation does not reflect any other investments that Ms. Henderson may own. Additionally, Ms. Henderson receives an annual salary of $843,640.00 as CFO at Apogee Therapeutics. Learn More about Jane Henderson's net worth.
How old is Jane Henderson?: Ms. Henderson is currently 58 years old. There are 4 older executives and no younger executives at Apogee Therapeutics. The oldest executive at Apogee Therapeutics is Dr. Rebecca Dabora Ph.D., Chief Development Officer, who is 64 years old. Learn More on Jane Henderson's age.
What is Jane Henderson's salary?: As the CFO of Apogee Therapeutics, Inc., Ms. Henderson earns $843,640.00 per year. There are 2 executives that earn more than Ms. Henderson. The highest earning executive at Apogee Therapeutics is Dr. Michael Thomas Henderson M.D., CEO & Director, who commands a salary of $1,170,000.00 per year. Learn More on Jane Henderson's salary.
How do I contact Jane Henderson?: The corporate mailing address for Ms. Henderson and other Apogee Therapeutics executives is 221 Crescent Street, Building 17 Suite 102b, Waltham, MA 02453, United States. Apogee Therapeutics can also be reached via phone at 650-394-5230 and via email at [email protected]. Learn More on Jane Henderson's contact information.
Has Jane Henderson been buying or selling shares of Apogee Therapeutics?: Jane Henderson has not been actively trading shares of Apogee Therapeutics over the course of the past ninety days. Most recently, Jane Henderson sold 6,000 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $48.26, for a transaction totalling $289,560.00. Following the completion of the sale, the chief financial officer now directly owns 200,871 shares of the company's stock, valued at $9,694,034.46. Learn More on Jane Henderson's trading history.
Who are Apogee Therapeutics' active insiders?: Apogee Therapeutics' insider roster includes Carl Dambkowski (Insider), Jane Henderson (CFO), and Michael Henderson (CEO). Learn More on Apogee Therapeutics' active insiders.
Are insiders buying or selling shares of Apogee Therapeutics?: In the last year, Apogee Therapeutics insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $990,800.00. In the last year, insiders at the sold shares 14 times. They sold a total of 215,530 shares worth more than $10,352,408.50. The most recent insider tranaction occured on December, 12th when Director Mark C Mckenna bought 20,000 shares worth more than $990,800.00. Insiders at Apogee Therapeutics own 36.1% of the company. Learn More about insider trades at Apogee Therapeutics.
Information on this page was last updated on 12/12/2024.

Jane Henderson Insider Trading History at Apogee Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/23/2024	Sell	6,000	$48.26	$289,560.00	200,871

Jane Henderson Buying and Selling Activity at Apogee Therapeutics

Apogee Therapeutics Company Overview

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $47.71

$45.51

$48.42

50 Day Range

MA: $50.60

$43.28

$61.12

2 Week Range

Now: $47.71

$24.88

$72.29

Volume

606,236 shs

Average Volume

504,083 shs

Market Capitalization

$2.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.3

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Jane Henderson Biography and Net Worth

What is Jane Henderson's net worth?

How old is Jane Henderson?

What is Jane Henderson's salary?

How do I contact Jane Henderson?

Has Jane Henderson been buying or selling shares of Apogee Therapeutics?

Who are Apogee Therapeutics' active insiders?

Are insiders buying or selling shares of Apogee Therapeutics?